La Jolla, CANCT06979362Now EnrollingIRB Ready

Heart Failure Clinical Trial in La Jolla, CA

Access cutting-edge heart failure treatment through this phase 2 clinical trial at a research site in La Jolla. Study-provided care at no cost to qualified participants.

Sponsored by Novo Nordisk A/S

Quick Self-Assessment

See if you qualify for this La Jolla location

Preparing your pre-screening questions…

Expert Care in La Jolla

Access heart failure specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related heart failure treatment provided free

Apply for This La Jolla Location

Check if you qualify for this heart failure clinical trial in La Jolla, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to La Jolla

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit La Jolla site if eligible
  4. 4Begin participation

About This Heart Failure Study in La Jolla

This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.

Sponsor: Novo Nordisk A/S

Who Can Participate

Inclusion Criteria

Age 40-84 years (both inclusive) at the time of signing the informed consent
Documented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening
Clinically stable and on optimised doses and unchanged drug classes of guideline-directed HF therapy ≥45 days prior to randomisation
Left ventricular ejection fraction ≥50% as assessed by echocardiography at screening, measured by central laboratory
Left ventricular hypertrophy assessed by echocardiography at screening measured by central laboratory with any of the following:
LVMi (greater than) \>88 gram per square meter (g/m\^2) for female participants and \>102 g/m\^2 for male participants, using the truncated ellipsoid method measured by central laboratory
LVMi \>95 g/m2 for female participants and \>115 g/m2 for male participants using the linear method (cube formula).
Interventricular septum diameter measured in diastole (IVSd) in the parasternal long axis view ≥1.1 cm for female participants and ≥1.2 cm for male participants.
Body mass index 18.5-40 kilogram per square meter (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1)
NT-proBNP ≥300 picograms per milliliter (pg/mL); NT-proBNP ≥600 pg/mL if atrial fibrillation/flutter is present at time of screening, measured by central laboratory

Exclusion Criteria

Estimated glomerular filtration rate lesser than (\<) 30 milliliter per minute (mL/min)/1.73 square meter (m\^2) at time of screening, measured by central laboratory
Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator, within 90 days prior to randomisation
Myocardial infarction, unstable angina pectoris or HF hospitalisation within 30 days prior to screening
Participants receiving intravenous HF medications within 45 days prior to randomisation
Participants with CRT, pacemaker or implantable cardioverter-defibrillator
Planned coronary revascularisation, pacemaker/cardioverter-defibrillator/CRT implantation, ablation of cardiac arrythmias and valve repair/replacement at the time of randomisation
Stroke or transient ischemic attack within 12 months prior to randomisation
Participants with potential disruption of the blood-brain barrier (e.g., multiple sclerosis), in the opinion of the investigator
Known history of severe liver disease and/or alanine aminotransferase or aspartate aminotransferase \>2.5 x upper limit of normal at screening, measured by central laboratory
Known genetic (or highly suspected due to family history) cause of increased cardiac mass (including dilated cardiomyopathy, Fabry disease and likely pathogenic or pathogenic variants within hypertrophic cardiomyopathy \[HCM\]).
Participants with suspected or diagnosed cardiac amyloidosis or sarcoidosis.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in La Jolla?

Yes, this clinical trial (NCT06979362) has an active research site in La Jolla, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure Treatment Options in La Jolla, CA

If you're searching for heart failure treatment options in La Jolla, CA, this clinical trial (NCT06979362) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our La Jolla research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure clinical trials near you to find additional studies recruiting in your area.

More Heart Failure Trials in La Jolla, CA

See all heart failure clinical trials recruiting in La Jolla — not just this study.

Browse Heart Failure Trials in La Jolla →

Browse More Trials by Condition

Heart Failure TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in La Jolla?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · La Jolla, CA